Literature DB >> 1678226

Nocturnal growth hormone release in children with short stature and atopic dermatitis.

T J David1, A P Ferguson, R W Newton.   

Abstract

This study was designed to test the hypothesis that children with atopic dermatitis and short stature fail to release growth hormone after falling asleep. Peak serum growth hormone response to arginine was compared with peak growth hormone concentration during sleep in 6 children with atopic dermatitis and short stature (greater than 3 SD below the mean) aged 7 to 12 years, and 5 control children aged 9 to 12 years without atopic dermatitis or asthma but with unexplained short stature (greater than 3 SD below the mean). All 5 control children achieved normal levels of growth hormone after falling asleep, whereas 3 of the 6 children with dermatitis did not. All patients with dermatitis were capable of releasing growth hormone after arginine stimulation. The results suggest that in some prepubertal children with atopic dermatitis and short stature there may be an impairment of growth hormone release during stage 4 sleep.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678226

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  4 in total

1.  Allergy and immunology in young children of Japan: The JECS cohort.

Authors:  Kiwako Yamamoto-Hanada; Kyongsun Pak; Mayako Saito-Abe; Limin Yang; Miori Sato; Makoto Irahara; Hidetoshi Mezawa; Hatoko Sasaki; Minaho Nishizato; Kazue Ishitsuka; Yukihiro Ohya
Journal:  World Allergy Organ J       Date:  2020-11-07       Impact factor: 4.084

2.  Linear growth in prepubertal children with atopic dermatitis.

Authors:  L Patel; P E Clayton; G M Addison; D A Price; T J David
Journal:  Arch Dis Child       Date:  1998-08       Impact factor: 3.791

3.  Nutrient intakes of infants with atopic dermatitis and relationship with feeding type.

Authors:  Youngshin Han; Youngmi Lee; Haeryun Park; Sunyoung Park; Kyunghee Song
Journal:  Nutr Res Pract       Date:  2015-01-05       Impact factor: 1.926

4.  Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.

Authors:  Hidehisa Saeki; Naoko Baba; Kazuhide Oshiden; Yuji Abe; Hidetsugu Tsubouchi
Journal:  J Dermatol       Date:  2019-11-11       Impact factor: 4.005

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.